Viridian Therapeutics Inc (VRDN)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$28.49

-0.06 (-0.21%)

Market Cap: $3.24B

Last updated: Nov 06, 2026 at 4:42 PM ET

Earnings

Performance (10Y)

Beat Rate

53%(21/40)

Avg Surprise

-82.74%

Streak

1 Q

Upcoming Estimates

Period ending Dec 31, 2026

EPS Consensus$-0.80

Range$-1.48 - $-0.29

13 analysts

Revenue Consensus

$20M

Range$7M - $41M

14 analysts

Last 12 of 40 reported quarters and 1 upcoming estimate

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.80	$-1.48 - $-0.29	-	-	13	-	-
Sep 30, 2026Sep 26 Reported Nov 4, 2026Reported Nov 4	$-0.81	$-1.01	$-1.26 - $-0.78	+19.80%	Beat	12	1 0 30d	-138.2%
Jun 30, 2026Jun 26 Reported Aug 6, 2026Reported Aug 6	$-1.05	$-0.97	$-1.22 - $-0.87	-8.25%	Miss	11	3 2 30d	-5.0%
Mar 31, 2026Mar 26 Reported May 5, 2026Reported May 5	$-0.90	$-1.08	$-1.29 - $-0.94	+16.67%	Beat	11	0 1 30d	-3.4%
Dec 31, 2025Dec 25 Reported Feb 26, 2026Reported Feb 26	$-1.08	$-0.90	$-1.32 - $-0.59	-20.00%	Miss	12	0 2 30d	-33.3%
Sep 30, 2025Sep 25 Reported Nov 5, 2025Reported Nov 5	$-0.34	N/A	-	+58.54%	Beat	10	1 3 30d	+70.4%
Jun 30, 2025Jun 25 Reported Aug 6, 2025Reported Aug 6	$-1.00	$-0.98	$-1.09 - $-0.81	-2.04%	Miss	12	3 5 30d	+2.0%
Mar 31, 2025Mar 25 Reported May 6, 2025Reported May 6	$-0.87	$-0.96	$-1.28 - $-0.84	+9.38%	Beat	9	3 1 30d	-10.1%
Dec 31, 2024Dec 24 Reported Feb 27, 2025Reported Feb 27	$-0.81	$-1.04	$-1.20 - $-0.84	+22.43%	Beat	12	1 6 30d	+40.0%
Sep 30, 2024Sep 24 Reported Nov 12, 2024Reported Nov 12	$-1.15	$-1.05	$-1.17 - $-0.80	-9.52%	Miss	14	No revisions (30d)	-5.5%
Jun 30, 2024Jun 24 Reported Aug 8, 2024Reported Aug 8	$-1.02	$-0.92	$-1.14 - $-0.69	-10.87%	Miss	15	No revisions (30d)	+19.7%
Mar 31, 2024Mar 24 Reported May 8, 2024Reported May 8	$-0.79	$-1.10	$-1.36 - $-0.81	+28.18%	Beat	12	No revisions (30d)	+50.9%
Dec 31, 2023Dec 23 Reported Feb 27, 2024Reported Feb 27	$-1.35	$-1.03	$-1.17 - $-0.84	-31.07%	Miss	13	No revisions (30d)	-19.5%

Key Metrics

Valuation
P/E Ratio	-7.42	EV/EBITDA	N/A
Price/FCF	-9.41x	FCF Yield	-10.63%
Profitability
Profit Margin	0.00%	Operating Margin	-401.80%
ROE	-83.70%	ROIC	-41.75%
Financial Health
Debt/Equity	0.42x	Interest Coverage	-15.75x
Current Ratio	14.46x	Quick Ratio	14.46x
Trading Statistics
Beta	1.07	Avg Volume	2.78M
52-Week High	$34.29	52-Week Low	$13.18

Technical Indicators Dashboard

Moving Averages

SMA 10$25.77

SMA 20$23.13

SMA 50$21.97

SMA 200$21.62

EMA 10$26.03

EMA 20$24.22

EMA 50$22.48

EMA 200$21.47

MACD

Line: 1.94Signal: 1.25Hist: 0.69

ADX

ADX: 44.4+DI: 41.5-DI: 10.1

Aroon & PSAR

Aroon Up92.0

Aroon Down16.0

PSAR$25.99

Bollinger Bands

Upper Band$29.87

Lower Band$16.39

%B Position5825%(Upper)

Band Width0.90

RSI (14-Day)

Overbought

77.0

Momentum Oscillators

Stoch %K89.5

Stoch %D90.4

Williams %R-14.1

ROC (10d)27.4%

Momentum6.12

CCI (20d)143.9

MFI (14d)82.4

Volatility Measures

ATR (14d)$1.33(4.7%)

StdDev (20d)3.37

Hist Vol72.7%(High)

Volume Flow

VWAP$28.60

OBV22.5M

AD Line-1.7M

CMF (20d)0.225

Volume Metrics

Avg Vol (20d)2.9M

Vol Ratio1.5x(High)

VWMA (20d)$24.35

Pivot Points

R3$30.41

R2$30.01

R1$29.28

Pivot Point$28.88

S1$28.15

S2$27.75

S3$27.02

Advanced Oscillators

TSI42.94

Ultimate Osc62.3

KST258.02

Financial Data

Quarter	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023
Total Revenue	$25.75M	$284,000	$141,000	$132,000	$70.57M	$75,000	$72,000	$72,000	$86,000	$72,000	$72,000	$72,000
Cost of Revenue	$1.53M	$117,000	$121,000	$320,000	N/A	N/A	N/A	$123,000	N/A	$5.79M	$345,000	$350,000
Gross Profit	$24.23M	$284,000	$141,000	$-188,000	$70.57M	$75,000	$72,000	$72,000	$86,000	$72,000	$72,000	$72,000

Operating Expenses	$127.70M	$126.55M	$116.31M	$122.56M	$110.58M	$106.84M	$93.94M	$87.54M	$83.57M	$72.26M	$55.97M	$71.55M
R&D	$70.09M	$71.58M	$77.63M	$89.21M	$86.26M	$86.63M	$76.83M	$71.96M	$69.16M	$56.19M	$40.94M	$38.56M
SG&A	$57.61M	$54.98M	$38.68M	$33.67M	$24.32M	$20.22M	$17.10M	$15.58M	$14.41M	$16.07M	$15.03M	$32.99M
Operating Income	$-103,477,000	$-126,268,000	$-116,169,000	$-122,749,000	$-40,013,000	$-106,767,000	$-93,866,000	$-87,472,000	$-83,480,000	$-72,187,000	$-55,897,000	$-71,478,000

Interest Income	$0	$8.49M	$7.87M	$7.79M	$5.52M	$6.55M	$7.54M	$8.61M	$7.79M	$7.79M	$7.94M	$5.53M
Interest Expense	$9.27M	$8.31M	$3.46M	$6.61M	$560,000	$514,000	$586,000	$858,000	$1.00M	$597,000	$587,000	$916,000
Income Before Tax	$-101,209,000	$-127,119,000	$-104,901,000	$-120,355,000	$-34,599,000	$-100,735,000	$-86,912,000	$-79,725,000	$-76,689,000	$-64,993,000	$-48,542,000	$-66,860,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$72.19M	$-145,000	$5.53M

Net Income	$-101,209,000	$-127,119,000	$-104,901,000	$-120,355,000	$-34,599,000	$-100,735,000	$-86,912,000	$-79,725,000	$-76,689,000	$-64,993,000	$-48,542,000	$-66,860,000

EBITDA	$-101,130,000	$-118,695,000	$-101,318,000	$-113,627,000	$-33,929,000	$-100,108,000	$-86,209,000	$-78,744,000	$-75,555,000	$-64,254,000	$-47,810,000	$-65,794,000
EBIT	$-101,473,000	$-118,812,000	$-101,439,000	$-113,747,000	$-34,039,000	$-100,221,000	$-86,326,000	$-78,867,000	$-75,685,000	$-64,396,000	$-47,955,000	$-65,944,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about VRDN

News

Healthy volunteers took part in the drug study Viridian will discuss Nov. 9

Viridian Therapeutics (VRDN) announced it will host a conference call on November 9, 2026, to present data from the VRDN-008 Phase 1 clinical trial conducted in healthy volunteers. The company will also discuss its...

Stock Titan•Nov 6, 2026 4:31 PM ET11/6/26•Neutral

Truist Securities maintains Viridian Therapeutics at Buy

Truist Securities has maintained its "Buy" rating for Viridian Therapeutics and increased its price target from $39 to $42...

TradingView•Nov 5, 2026 11:10 AM ET11/5/26•Bullish

What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call

Viridian Therapeutics reported strong Q3 earnings for its thyroid eye disease treatment, Lumvoa, exceeding expectations with $24.7 million in net product revenue in its first quarter on the market. The company ended...

TradingView•Nov 4, 2026 5:10 PM ET11/4/26•Somewhat-Bullish

Viridian Therapeutics Posts $24.7 Million in Lumvoa Net Product Revenue for Q3 2026

Viridian Therapeutics reported $24.7 million in Lumvoa net product revenue for the third quarter of 2026, contributing to a total revenue of $25.752 million. The company recorded a GAAP net loss per share of $0.81...

www.tokenpost.com•Nov 4, 2026 4:33 PM ET11/4/26•Somewhat-Bullish

Stifel raises Viridian Therapeutic stock price target on strong Lumvoa launch

Stifel has increased its price target for Viridian Therapeutics (NASDAQ:VRDN) to $43.00 from $40.00, reiterating a Buy rating...

Investing.com•Nov 4, 2026 11:07 AM ET11/4/26•Bullish

VRDN Valuation and Fair Value

P/E: -7.4x
Forward P/E: 1.0x
P/FCF: -9.4x
P/B: 5.6x

See GNG's fair value

VRDN Profitability: Margins, ROIC and FCF

Gross margin: 93.0%
Operating margin: -401.8%
Net margin: 0.0%
ROIC: -41.8%
ROE: -83.7%
FCF margin: -1305.4%
FCF yield: -10.6%

VRDN Competitors

Company	Ticker
Enliven Therapeutics Inc.	ELVN
Dyne Therapeutics Inc	DYN
National HealthCare Corporation	NHC
Telix Pharmaceuticals Limited	TLX
Tarsus Pharmaceuticals Inc	TARS
Denali Therapeutics Inc	DNLI
Celcuity LLC	CELC
Surgery Partners Inc	SGRY

Sector: Healthcare

VRDN Analyst Ratings

Consensus: Buy
Analysts: 17
Strong Buy: 3
Buy: 14
Hold: 0
Sell: 0
Strong Sell: 0

VRDN Bull Case vs Bear Case

Bull case

100.0% of VRDN's analyst ratings are Buy or Strong Buy.

Bear case

VRDN's quarterly revenue changed -63.5% year over year.

VRDN Earnings: Beat Rate and Next Report

Beat rate: 5 of 8 quarters (62.5%)
Average surprise: 12.1%
EPS estimate (fiscal period ending Dec 31, 2026): $-0.80

VRDN Earnings Date

VRDN reports Feb 24, 2027, after the close. The date is estimated.

VRDN ETF Holders

GNG tracks 11 ETFs that hold VRDN. The largest weights:

State Street SPDR S&P Biotech ETF (XBI), 0.59% of the fund
First Trust Small Cap Growth AlphaDEX Fund (FYC), 0.42% of the fund
BlackRock Health Sciences Trust (BME), 0.17% of the fund
Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.08% of the fund
iShares Russell 2000 ETF (IWM), 0.04% of the fund

Open the ETF Stock Exposure tool for VRDN

See insider activity

Frequently Asked Questions About VRDN

When does VRDN report earnings?

Viridian Therapeutics Inc (VRDN) is expected to report earnings on Feb 24, 2027.

Does VRDN pay dividends?

Viridian Therapeutics Inc (VRDN) does not currently pay a regular dividend.

What is VRDN's market cap?

Viridian Therapeutics Inc (VRDN) has a market capitalization of $3.24B with a current stock price of $28.49.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In